-$0.37 EPS Expected for CytomX Therapeutics, Inc. (NASDAQ:CTMX) This Quarter

Brokerages predict that CytomX Therapeutics, Inc. (NASDAQ:CTMXGet Rating) will announce ($0.37) earnings per share for the current quarter, according to Zacks. Five analysts have issued estimates for CytomX Therapeutics’ earnings, with estimates ranging from ($0.51) to ($0.25). CytomX Therapeutics reported earnings of ($0.30) per share during the same quarter last year, which would indicate a negative year over year growth rate of 23.3%. The company is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that CytomX Therapeutics will report full year earnings of ($1.44) per share for the current fiscal year, with EPS estimates ranging from ($1.94) to ($1.08). For the next year, analysts expect that the firm will post earnings of ($1.61) per share, with EPS estimates ranging from ($2.31) to ($1.18). Zacks’ EPS calculations are an average based on a survey of analysts that cover CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMXGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). CytomX Therapeutics had a negative return on equity of 91.89% and a negative net margin of 129.97%. During the same period in the previous year, the business posted ($0.26) EPS.

A number of brokerages recently commented on CTMX. StockNews.com lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 27th. Wedbush dropped their target price on CytomX Therapeutics from $10.00 to $6.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 10th. JPMorgan Chase & Co. dropped their target price on CytomX Therapeutics from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 2nd. Piper Sandler dropped their target price on CytomX Therapeutics from $16.00 to $10.00 in a research report on Friday, May 27th. Finally, Zacks Investment Research lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, CytomX Therapeutics currently has an average rating of “Buy” and an average price target of $9.59.

Institutional investors and hedge funds have recently modified their holdings of the business. Macquarie Group Ltd. increased its stake in shares of CytomX Therapeutics by 515.1% in the 3rd quarter. Macquarie Group Ltd. now owns 4,853 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 4,064 shares during the last quarter. Mackenzie Financial Corp purchased a new position in shares of CytomX Therapeutics during the 1st quarter worth $35,000. Delphia USA Inc. purchased a new position in shares of CytomX Therapeutics during the 1st quarter worth $39,000. Lazard Asset Management LLC purchased a new position in CytomX Therapeutics during the 1st quarter valued at about $40,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in CytomX Therapeutics during the 4th quarter valued at about $44,000. 92.34% of the stock is owned by institutional investors and hedge funds.

NASDAQ CTMX traded up $0.15 during trading hours on Tuesday, reaching $1.89. The stock had a trading volume of 1,105,661 shares, compared to its average volume of 937,930. The stock has a fifty day moving average of $1.98 and a 200 day moving average of $3.63. The stock has a market cap of $123.60 million, a P/E ratio of -1.33 and a beta of 0.76. CytomX Therapeutics has a 52-week low of $1.51 and a 52-week high of $7.53.

About CytomX Therapeutics (Get Rating)

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

Featured Stories

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Want More Great Investing Ideas?

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.